Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study-Reference-Cited by-同舟云学术

Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

Published:2021-12 Issue: Volume: Page:
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Schuster Michael,Zijlstra Josée,Casasnovas Rene-Olivier,Vermaat Joost S.P^ORCID,Kalakonda Nagesh,Goy Andre,Choquet Sylvain,Neste Eric Van Den,Hill Brian,Thieblemont Catherine,Cavallo Federica^ORCID,De la Cruz Fatima,Kuruvilla John,Hamad Nada^ORCID,Jaeger Ulrich,Caimi Paolo,Gurion Ronit,Warzocha Krzysztof,Bakhshi Sameer,Sancho Juan-Manuel^ORCID,Follows George,Egyed Miklos,Offner Fritz,Vassilakopoulos Theodoros,Samal Priyanka,Ku Matthew,Ma Xiwen,Corona Kelly,Chamoun Kamal,Shah Jatin,Shacham Sharon,Kauffman Michael G.,Canales Miguel^ORCID,Maerevoet Marie

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference36 articles.

1. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma;Skrabek;Curr Oncol,2019

2. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP;Sehn;Blood,2007

3. The Genetic Landscape of Diffuse Large B-Cell Lymphoma;Pasqualucci;Semin Hematol,2015

4. New drugs for the management of relapsed or refractory diffuse large B-cell lymphoma;Sarkozy;Ann Lymphoma,2019

5. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy;Maurer;J Clin Oncol,2014

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sequencing therapy in relapsed DLBCL;Hematology;2022-12-09